




## **Correction:** Joseph et al. Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report. *Pharmaceuticals* 2023, *16*, 1164

Boney Joseph <sup>1,2,†</sup>, Nicolas A. Nunez <sup>1,†</sup>, Simon Kung <sup>1</sup>, Jennifer L. Vande Voort <sup>1</sup>, Vanessa K. Pazdernik <sup>3</sup>, Kathryn M. Schak <sup>1</sup>, Stacey M. Boehm <sup>1</sup>, Brooke Carpenter <sup>1</sup>, Emily K. Johnson <sup>1</sup>, Grigoriy Malyshev <sup>1</sup>, Nathan Smits <sup>1</sup>, Daniel O. Adewunmi <sup>1</sup>, Sarah K. Brown <sup>1</sup> and Balwinder Singh <sup>1,\*,†</sup>

- <sup>1</sup> Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN 55905, USA
- <sup>2</sup> Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
- <sup>3</sup> Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA
  - \* Correspondence: singh.balwinder@mayo.edu
  - <sup>+</sup> These authors contributed equally to this work.

## **Error in Figure**

In the original publication [1], there were mistakes in the Figure 2B. The correct Figure 2B appear below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.



**Figure 2.** (**A**) Mean percent change in QIDS-SR 16 scores from baseline after each treatment and (**B**) mean CADSS score during treatment based on lamotrigine usage (N = 48). Abbreviations—CADSS: Clinician-Administered Dissociative Status Scale; QIDS-SR: 16-item Quick Inventory of Depressive Symptomatology self-report.



Citation: Joseph, B.; Nunez, N.A.; Kung, S.; Vande Voort, J.L.; Pazdernik, V.K.; Schak, K.M.; Boehm, S.M.; Carpenter, B.; Johnson, E.K.; Malyshev, G.; et al. Correction: Joseph et al. Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report. *Pharmaceuticals* 2023, *16*, 1164. *Pharmaceuticals* **2023**, *16*, 1571. https://doi.org/10.3390/ ph16111571

Received: 19 October 2023 Accepted: 26 October 2023 Published: 7 November 2023



**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).

## Reference

 Joseph, B.; Nunez, N.A.; Kung, S.; Vande Voort, J.L.; Pazdernik, V.K.; Schak, K.M.; Boehm, S.M.; Carpenter, B.; Johnson, E.K.; Malyshev, G.; et al. Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report. *Pharmaceuticals* 2023, *16*, 1164. [CrossRef] [PubMed]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.